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by Robert M. Pratt*
Glucocorticoids (triamcinolone) and dioxins (TCDD) are highly specific teratogens in the mouse, in that
cleft palate is the major malformation observed. Glucocorticoids and TCDD both readily cross the yolk
sac and placenta and appear in the developing secondary palate. Structure-activity relationships for glu-
cocorticoid- and TCDD-induced cleft palate suggest a receptor involvement. Receptors for glucocorticoids
and TCDD are present in the palate and their levels in various mouse strains are highly correlated with
their sensitivity to cleft palate induction. Receptors for glucocorticoids appear to be more prevalent in
the palatal mesenchymal cells whereas those forTCDD are probably located in the palatal epithelial cells.
Glucocorticoids exert their teratogenic effect on the palate by inhibiting the growth of the palatal mes-
enchymal cells whereas TCDD alters the terminal cell differentiation ofthe medial palatal epithelial cells.
Glucocorticoid-Induced Cleft Palate
Glucocorticoids administered to several species of ex-
perimental animals atmidgestationinhibit complete for-
mation of the secondary palate (1-4). Development of
the mammalian secondary palate is a complex process
that depends upon the presence of various hormones
and growth factors (5). The palatal shelves first appear
as outgrowths from the maxillary process and subse-
quently grow in averticalposition alongside the tongue.
The shelves undergo a rapid reorientation to the hori-
zontal position above the tongue which brings the ap-
posing epithelia into contact at the midline. The medial
epithelial cells then undergo a programmed cell death
withresorptionofthe basementmembrane and cell rem-
nants, and the two shelves fuse into a single tissue, the
secondary palate, which separates the oral and nasal
cavities (6,7).
Different strains ofinbred mice exhibit different de-
grees of susceptibility to glucocorticoid-induced cleft
palate (1,8). All of the surviving offspring of A/J mice
treated with glucocorticoids between days 11 and 15 of
gestation have cleft palate, whereas C57BL/6J mice
treated with the same dose produce 20 to 25% offspring
with cleft palate (8-10). A number of mechanisms have
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been proposed to explain the different responses ofvar-
ious strains of mice to the teratogenic action of gluco-
corticoids (5,11,12). Walker and Fraser (6) showed that
during normal development, the palatal shelves became
horizontal laterinthe A/J thanthe C57BL/6J strain and
suggested that this difference makes A/J mice more
susceptible to cortisone than C57BL/6J mice (13). A
recent study utilizing frozen sections (14) showed that,
in addition to delaying palatal shelfelevation, cortisone
treatment severely reduced the extent of contact be-
tween the palatal shelves in A/J mice. Although contact
was present in 20% ofthe cortisone-treated fetuses, the
mean area of the shelf contact was only 20% of that in
control palates. Therefore, the net shelf contact in cor-
tisone-treated litters was only 4% of the potential con-
tact in control litters. Other studies in which shelfcontact
was assessed in glucocorticoid-treated fetuses reported
contact in 27-30% ofthe fetuses. However, this limited
contact, observed between the shelves in the midpalate
region, was considered adequate for complete palatal
fusion, and a failure in the fusion mechanism was pro-
posed as an alternative (4,15). Diewert and Pratt (14)
alsoobserved shelfcontactinthemidpalateregion; how-
ever, the shelves remained separated in the anterior
and posterior regions. Since contact between the shelves
normally occurs first in the midpalate region, some con-
tact in this region would be expected with cortisone
treatment; the presence of a small area of contact in
some cortisone-treated palates cannot be considered
equivalent to the extensive contact present in controls.R. M. PRATT
Studies ofeffects ofglucocorticoids on the palatal ep-
ithelium suggested that there may be significant differ-
ences between tissue responses in vitro and in vivo.
Recent investigations of the in vivo effects of triamci-
nolone on palatal epithelium inthe sensitive CF1 mouse
line showed thatdegenerative events were delayed, but
not prevented (16,17). These results suggested that ef-
fects of glucocorticoid on degenerative changes in the
epithelium were not responsible for palatal clefting in
vivo. However, studies ofglucocorticoids in vitro were
reported tocausechangesinthemedialepithelium. Cor-
tisol was reported to prevent medial epithelial break-
down inthe sensitive A/J strain, but notinthe resistant
C57BL/6J strain (18). Based on the results ofprevious
in vitro studies showing palatal fusion in the presence
of hydrocortisone (19,20), differences in culture condi-
tions appear to have significant effects on the results.
Therefore, although the palatal epithelium may be af-
fected by teratogens in vitro, these effects are not sim-
ilar to the major effect contributing to development of
cleft palate in vivo.
Other possible explanations of strain differences in
response to glucocorticoid-induced cleft palate are me-
tabolism, level ofendogenous steroids, and differential
distribution ofthe steroid in maternal and fetal tissues.
Additionally, there might be differences in sensitivity
ofembryonic facial structures toward the steroid. Var-
iations in the endogenous levels of glucocorticoids in
sensitive and resistant strains were not correlated with
the sensitivity ofthe strains to steroids; there were not
significant differences between A/J and C57BL/6J mice
in the concentration of maternal or fetal corticosterone
during midgestation (21). Glucocorticoids can cross the
rodent placenta without being metabolized. When ad-
ministered in pharmacologic doses to pregnant mice, a
large fraction of the administered steroid reached em-
bryos unmetabolized and appeared to function as the
active teratogenic agent (22).
Glucocorticoid effects in adult and fetal tissues are
mediated through the interaction of the hormone with
specific intracellular receptor proteins in the cyto-
plasmic fraction of target cells. Schmidt and Litwack
(23) proposed a five-step model for activation of the
glucocorticoid-receptor complex. The receptor, which is
a protein of 87,000 molecular weight (24) is present in
the cytoplasm in aformthat isphosphorylated, contains
reduced sulfhydryl groups, and is capable of binding
glucocorticoid. The unbound receptor may have asso-
ciated with it alowmolecular weight, heat-stable factor
that maintains the protein in a conformation favorable
for steroid binding and inhibits the subsequent activa-
tion. The phosphorylated receptor protein binds glu-
cocorticoid to form an unactivated complex. This complex
then undergoes a confonnational change (activation) that
results in the exposure ofpositively charged amino acid
residues and hence an increased affinity for polyanions
like DNA. During the activation step, the receptor or
another component becomes dephosphorylated. Like-
wise, activation also may involve the dissociation of a
low molecular weight, heat-stable factor which, when
associated with the receptor, blocks activation. The ac-
tivated glucocorticoid-receptor complex then translo-
cates to the nucleus where it binds to chromatin acceptor
sites and alters the transcription of specific genes. The
steroid eventually dissociates from the nuclearreceptor
protein, and may then be recycled to the cytoplasm
where it can be either degraded orreactivated with the
heat-stable factor.
The appearance in specific embryonic tissues of cy-
toplasmic glucocorticoid receptors at discrete develop-
mental stages has been implicated as one factor that
determines the appearance ofhormonal responsiveness
in these tissues (25). Likewise, the presence of func-
tional nuclear acceptor proteins forthe steroid-receptor
complex is also required for embryonic target tissues
about to undergo hormone-dependent differentiation (26,
27).
Most evidence suggests that glucocorticoid terato-
genicity is due to direct action on the embryo. The total
binding of labeled glucocorticoid to palatal and other
embryonic tissue proteins varied in different strains of
mice and correlated with the teratologic responsiveness
ofthe strains to glucocorticoids. Salomon and Pratt (5,28-
30) demonstrated that mouse embryonic palatal mes-
enchyme cells possess high affinity, specific receptor
proteins for glucocorticoid. The synthetic glucocorti-
coids dexamethasone and triamcinolone acetonide (TA)
have a higher affinity for these receptors than the nat-
ural glucocorticoid hydrocortisone (HC), and a struc-
ture-activity study has shown that their affinity
correlated well with their teratogenicity (31); TA was
found tobe40times as potent as HC and twice as potent
as DEX (32).
Although the glucocorticoid receptors in embryonic
mouse palatal shelveshave notbeenbiochemicallychar-
acterized, various properties of receptors prepared from
whole day-13 A/J and C57BL/6J mouse embryos have
been studied (32). Embryoniccytosols fromboth strains
were found to contain high affinity, limited capacity
binding proteins for dexamethasone and triamcinolone
acetonide, which bind both natural and synthetic glu-
cocorticoids, and can be distinguished from serum cor-
ticosteroid binding globulin (transcortin) by their heat
sensitivity, sedimentation, gel filtration properties, and
sensitivity to sulfhydryl reagents. These embryonic re-
ceptor proteins appear to be indistinguishable from adult
glucocorticoid receptor protein found in the liver.
Embryonic A/J facial mesenchyme cells, both freshly
isolated and in primary culture, possessed two to three
times more cytoplasmic receptors than C57BL/6J mes-
enchyme cells (28). Strain differences in the concentra-
tion of cytoplasmic receptors for glucocorticoids in the
day-14embryoweregenerallyrestrictedtothe orofacial
region (5). Several investigators (5,33,34) showed that
the levels ofcytoplasmic glucocorticoid receptor in fetal
palate and adultlivercytosols were correlatedwith sen-
sitivity to glucocorticoid-induced cleft palate. In one case
these results were not corroborated. Utilizing whole
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mouse fetal heads and an unconventional method ofcy-
tosol preparation, Hackney (35) did not find a positive
correlation between triamcinolone acetonide binding and
cleft palate sensitivity in A/J, C3H and C57BL/6J mice.
Salomonand Pratt(5)reportedthatthe concentration
of glucocorticoid receptors in day-14 Swiss Webster
mouse embryos was higher in the orofacial region than
that observed in the liver, brain or forelimb. The bio-
chemical basis forthe increased level ofreceptors in the
palate is not understood but may indicate that the de-
veloping secondary palate is dependent on a high level
ofglucocorticoid receptors fornormaldevelopment. The
location of these glucocorticoid receptors in the devel-
oping palate appears to be predominantly in the mes-
enchymal cells as revealed by autoradiographic and
immunocytochemical methods (35).
Information concerning the level ofglucocorticoid re-
ceptors present in the developing human palatal shelf
is of great interest. Yoneda and Pratt (37) have estab-
lished a line of human embryonic palatal mesenchymal
cells (HEPM) from a human abortus in the prefusion
stage ofpalatal development and found that these cells
contained approximately tenfold higher levels of glu-
cocorticoid receptors than primary cell cultures from
mouse palatal shelves. However, it should be pointed
outthatcomparison ofestablished celllines and primary
cell cultures may not be valid. These HEPM cells have
proved to be useful for understanding the complex hor-
monal regulation ofpalatal growth and differentiation.
Yoneda et al. (38) recently reported a study in which
various fibroblastic cell lines, from tissues ofindividuals
withcleftlipand/orcleftpalate, were examined forlevel
ofglucocorticoid receptors. Skinpunches were obtained
from various affected and normal individuals in addition
to oral tissue obtained during surgery from sites of lip
or palate repair. A significant deficiency in glucocorti-
coid receptors was noted in the cell lines from clefted
individuals. Although these tissues are older than the
developing embryonic primary and secondary palate,
the results were interpreted as indicating that a defect
in the complex hormonal regulatory mechanism for em-
bryonic growth may have occurred and persisted into
various neonatal or adult tissues. Since this was a pre-
liminary study with only a limited number of cell lines,
this work must be expanded before definitive conclu-
sions can be drawn.
Experimental modulation of receptor number or ac-
tivity would provide further evidence ofinvolvement in
glucocorticoid-induced cleft palate. Yoneda and Pratt
(39) have reported that the level of vitamin B6 exerted
a large influence of glucocorticoid-induced cleft palate
in Swiss Webster mice. When the maternal vitamin B6
level was increased by administration in the drinking
water, cortisone-induced cleft palate decreased, in con-
trast with the increase in the cleft palate frequency
observed when animals were placed on a vitamin B6-
deficient diet. This effect was interpreted as being due
to the direct interaction in the palatal shelf of vitamin
B6 with the DNA binding site of the glucocorticoid re-
ceptor (40), thereby strongly influencing the amount of
steroid-receptor complex that enters the nucleus and
therefore also the resultant biological response.
The effects of glucocorticoids on primary cultures of
mouse embryonic palatal mesenchyme cells have been
studied in vitro (29,41). Glucocorticoid (at 106 to 108
M) caused areduction in cellnumberand asimultaneous
decrease in the incorporation of labeled thymidine in
DNA in both A/J, C57BL/6J and human embryonic pal-
atal mesenchyme cells. These cells synthesize collagen
which constitutes approximately 7 to 10% of the total
protein. Cells cultured in the presence of dexametha-
sone synthesized decreased amounts of both collagen
and noncollagen proteins (5), but to a greater extent in
A/J than in comparably treated C57BL/6J cells. A/J
cells, possessing a higher level of glucocorticoid recep-
tors, were alsomore sensitivetotheinhibitionofgrowth
and of thymidine incorporation than C57BL/6J cells.
Differential effects on DNA synthesis and growth were
observed in organ cultures of palatal shelves from A/J
and C57BL/6J mice in the presence of dexamethasone
or hydrocortisone (42,43). These results are in accord
with observations that dexamethasone and cortisone in-
hibited the in vivo proliferation ofmesenchymal cells of
rat and mouse palatal processes (3,44,45). This inhibi-
tion of mesenchymal cell growth is a key factor in pro-
ducing glucocorticoid-induced cleft palate (14) which is
mediated by areceptor-dependent mechanism, presum-
ably involving altered transcription of a key enzyme or
protein in the palate (46). Recently, Grove et al. (47)
provided evidence for a correlation between alteration
in phosphatidylinositol turnover at the cell surface and
growth inhibition induced by dexamethasone in human
palatal mesenchymal cells.
Physiological levels of glucocorticoids (10' M) pro-
mote DNA synthesis and stimulate human and mouse
palatal mesenchyme cell growth. Therefore, glucocor-
ticoids at physiological concentrations either alone or
through interactions with other hormones or growth
factors may control certain stages of normal palatoge-
nesis. Dexamethasone administered in vivo to A/J and
C57BL/6J mice causes an increase in palatal glutamine
synthetase which may be essential for expression of
various mesenchymal or epithelial cell surface proteins
(48).
Glucocorticoids are important regulators of carbo-
hydrate, protein, and fat metabolism in adult tissues
(49). Glucocorticoids also perform important functions
during various stages of embryonic and fetal develop-
ment (50). Glucocorticoids, either alone or with other
hormones such as thyroxine, insulin, and growth fac-
tors, control the morphological and biochemical differ-
entiation of a variety of fetal and postnatal tissues.
Dioxins and Their Receptors in
Teratology
2,3,7,8-Tetrachlorodibenzo-p-dioxin(TCDD)servesas
the prototype for a large group of halogenated aroma-
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tic hydrocarbons [chlorinated dibenzo-p-dioxin, di-
benzofuran, azo(xy)benzene, biphenyl, and naphthalene
isomers and brominated biphenyl isomers], which are
all approximate isostereomers, produce a similar and
characteristic pattern of toxic and biochemical re-
sponses, andarethoughttoactbyacommonmechanism
(51-53).
The administration ofTCDD (and congeners) to lab-
oratory animals induces the coordinate expression of a
battery of enzymes, including the activity of the cyto-
chrome P450-mediated microsomal monooxygenase aryl
hydrocarbon hydroxylase in liver and a variety ofother
tissues (54). This pleiotropic response is initiated by the
stereospecific, reversiblebindingofTCDDtoacytosolic
protein, termed the induction receptor, and by the
translocation ofthe ligand-receptor complex to the nu-
cleus (55-57). In mice there is a genetic polymorphism
at the locus that determines the receptor, the Ah locus
(58). Inbred strains ofmice carryingtheAhb allele (e.g.,
C57BL/6J) have a high affinity receptor and are sensi-
tive to the induction of AHH activity by TCDD; other
inbred strains possessing the Ahd allele (e.g., DBA/2)
have a lower affinity receptor and are less sensitive to
enzyme induction byTCDD. In crosses andbackcrosses
between C57BL/6J and DBA/2 mice, expression ofthe
Ahb allele is either dominant or codominant, depending
on the assay used for phenotyping.
The toxic responses produced by halogenated aro-
matic hydrocarbons are quite characteristic; however,
many of the lesions are highly species-specific (59-61).
Following the administration of a lethal dose of TCDD
or one of its congeners virtually all species experience
a prolonged wasting syndrome prior to death, with loss
of adipose tissue, involution of lymphoid organs, and
degeneration ofthe seminiferous tubules ofthe testicle.
In contrast, the more distinctive lesions involve prolif-
eration and/or metaplasia of epithelial tissues such as
skin, stomach, intestines, and urinary tract, and occur
in a limited number ofspecies. Similarly, the presence
and severity of hepatic pathology vary considerably
among species. The cause of death is unknown.
Two independent lines of evidence indicate that the
toxic responses to TCDD and its congeners are me-
diated by theirbinding to the induction receptor. First,
for a large number of halogenated aromatic hydrocar-
bons, the rank ordered structure-activity relation for
their receptor affinity or their potency to induce AHH
activity corresponds to their toxic potency (measured
as the mean lethal dose, LD50, or dose reported to pro-
duce a specific toxic response) (51,53,62,63). Second,
toxicresponsesproducedbyTCDDinmice, e.g., thymic
involution, cleft palate formation in the fetus, and he-
patic porphyria, have been found to segregate with the
Ah locus (64,65). In DBA/2J, RF/J, AKR/J, SWR/J,
and 129/J, the five mouse strains with a low affinity
receptor, TCDD produced 0 to 3% incidence of cleft
palate. Four of the five strains with a high affinity re-
ceptor, C57BL/6J, A/J, BALB/cByJ and SEC/1REJ,
developed a 54 to 95% incidence in response to TCDD.
CBA/J was the only strain with a high affinity receptor
that did not develop cleft palate and these mice are also
resistant to cortisone-induced cleft palate (65). A recent
study (66) has shown that ,-naphthoflavone, which is
another ligand of the Ah-receptor but which does not
produce cleft palate by itself, was found to increase the
frequency of TCDD-induced cleft palate when co-ad-
ministered. In addition to the polysubstrate monooxy-
genase system, other enzyme systems not related to
metabollc conversion of polycyclic hydrocarbons are
considered to be structural gene products of the Ah
locus. 3-Naphthoflavone may induce a number of en-
zymes also stimulated by TCDD but in a different pat-
tern and insufficient for cleft palate induction.
Galloway et al. (67) found that the inducible cyto-
chrome P1-450 enzyme system is expressed in mouse
embryos explanted from the uterus at day 7.5 or 8.5 of
gestation. These results imply that the regulatory gene
product (Ah receptor) and the structural gene product
(cytochrome P1-450) are both functional from an early
embryonic age. The Ah locus is most likely responsible
forinducible benzo(a)pyrene metabolism and associated
embryotoxicity and teratogenesis in the mouse embryo
at or soon after day 7 of gestation.
DenckerandPratt(68) showedthatembryonicpalatal
shelves from C57BL/6J, acleftpalate-responsive mouse
strain (69), have high levels of a specific cytoplasmic
receptor for TCDD with similar biochemical character-
istics as the adult liver. A nonresponsive strain, AKR/J,
on the other hand, showed no specific TCDD binding in
adult liver or any embryonic tissue and was resistant
to the induction of cleft palate by TCDD (67). Studies
using frozen sections (70) showed that TCDD-treated
C57BL/6J palatal shelves made firm and extensive con-
tact at their medial epithelium in vivo, in contrast with
that found with A/J glucocorticoid-treated palatal shelves
in vivo (14). TCDD administered on day 10 (71), at a
teratogenic dose for the mouse palate, crossed the vis-
ceral yolk sac and/or chorioallantoic placenta and was
present in the embryo at nanomolar concentrations,
which is similartothe equilibriumbindingconstant (Kd)
found in the palatal shelves (68).
Therefore, it appears that TCDD exerts a direct ef-
fect onthemidgestation embryo to produce cleft palate.
This effect appears to be limited to an alteration in the
complex process of terminal cell differentiation of the
medialepithelialcells. The knownmajoreffect ofTCDD
onhumanbeings, i.e., chloracne, has also been ascribed
to an effect on epidermal cell differentiation (52) and
actually results in enhanced epidermal proliferation. It
is surprising that Ah receptors would be present in
embryos, since the known ligands, TCDD and
benzo(a)pyrene, are not compatible with normal devel-
opment. TheAhreceptor-ligand complexmayhave once
served in evolution as a hormone or growth factor for
a variety of ectodermally derived tissues. If so, it is
conceivable that the Ah receptor now exists in various
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tissues without a natural ligand and is activated only
when tissues are exposed to potent dioxins such as
TCDD.
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